Turmoil in the financial markets is having a disproportionate impact on biotech – and coupled with extra caution from regulators, is threatening innovation.
UK biotech Phynova makes a business out of developing traditional medicines, but when it comes to raising money it is pioneering a new, low-cost route to American investors.
Private equity firm Celtic Pharma is launching two new funds worth $1.5 billion in total, to invest in development-stage biotech companies and products.
Consumer products giant Procter and Gamble is applying its knowledge of consumers to the development of new medicines – and wants to share its insights with biotech companies.
The claim that over-patenting hinders the development of new treatments is not supported by the evidence, says the US Biotechnology Industry Organization.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.